New combo therapy shows promise for rare chest cancer

NCT ID NCT06019468

Recruiting now Disease control Sponsor: Shanghai Pulmonary Hospital, Shanghai, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining the drug envolizumab with radiation therapy before surgery can safely shrink tumors in people with locally advanced thymic carcinoma. About 25 adults aged 18-75 with stage III-IVA disease who have not had prior treatment will receive the combination, then undergo surgery. The goal is to see how many patients have their tumors shrink or disappear, and to establish better treatment standards for this rare cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thymic carcinoma thymoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYMIC CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai Pulmonary Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

Contact Email: •••••@•••••